MiR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma

Daisuke Kubota, Nobuyoshi Kosaka, Tomohiro Fujiwara, Akihiko Yoshida, Yasuhito Arai, Zhiwei Qiao, Fumitaka Takeshita, Takahiro Ochiya, Akira Kawai, Tadashi Kondo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Osteosarcoma is the most common primary malignancy in bone. Patients who respond poorly to induction chemotherapy are at higher risk of adverse prognosis. The molecular basis for such poor prognosis remains unclear. We investigated miRNA expression in eight open biopsy samples to identify miRNAs predictive of response to induction chemotherapy and thus maybe used for risk stratification therapy. The samples were obtained from four patients with inferior necrosis (Huvos I/II) and four patients with superior necrosis (Huvos III/IV) following induction chemotherapy. We found six miRNAs, including miR-125b and miR-100, that were differentially expressed > 2-fold (p < 0.05) in patients who respond poorly to treatment. The association between poor prognosis and the abundance of miR-125b and miR-100 was confirmed by quantitative reverse transcriptase-polymerase chain reaction in 20 additional osteosarcoma patients. Accordingly, overexpression of miR-125b and miR-100 in three osteosarcoma cell lines enhanced cell proliferation, invasiveness, and resistance to chemotherapeutic drugs such as methotrexate, doxorubicin, and cisplatin. In addition, overexpression of miR-125b blocked the ability of these chemotherapy agents to induce apoptosis. As open biopsy is routinely performed to diagnose osteosarcoma, levels of miR-125b and miR-100 in these samples may be used as basis for risk stratification therapy.

Original languageEnglish
Article number1390571
JournalSarcoma
Volume2016
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

Induction Chemotherapy
Osteosarcoma
Biomarkers
MicroRNAs
Necrosis
Biopsy
Reverse Transcriptase Polymerase Chain Reaction
Methotrexate
Doxorubicin
Cisplatin
Therapeutics
Cell Proliferation
Apoptosis
Bone and Bones
Drug Therapy
Cell Line
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Kubota, D., Kosaka, N., Fujiwara, T., Yoshida, A., Arai, Y., Qiao, Z., ... Kondo, T. (2016). MiR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma. Sarcoma, 2016, [1390571]. https://doi.org/10.1155/2016/1390571

MiR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma. / Kubota, Daisuke; Kosaka, Nobuyoshi; Fujiwara, Tomohiro; Yoshida, Akihiko; Arai, Yasuhito; Qiao, Zhiwei; Takeshita, Fumitaka; Ochiya, Takahiro; Kawai, Akira; Kondo, Tadashi.

In: Sarcoma, Vol. 2016, 1390571, 2016.

Research output: Contribution to journalArticle

Kubota, D, Kosaka, N, Fujiwara, T, Yoshida, A, Arai, Y, Qiao, Z, Takeshita, F, Ochiya, T, Kawai, A & Kondo, T 2016, 'MiR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma', Sarcoma, vol. 2016, 1390571. https://doi.org/10.1155/2016/1390571
Kubota, Daisuke ; Kosaka, Nobuyoshi ; Fujiwara, Tomohiro ; Yoshida, Akihiko ; Arai, Yasuhito ; Qiao, Zhiwei ; Takeshita, Fumitaka ; Ochiya, Takahiro ; Kawai, Akira ; Kondo, Tadashi. / MiR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma. In: Sarcoma. 2016 ; Vol. 2016.
@article{be73079ad7304ed98121ca36582e4d54,
title = "MiR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma",
abstract = "Osteosarcoma is the most common primary malignancy in bone. Patients who respond poorly to induction chemotherapy are at higher risk of adverse prognosis. The molecular basis for such poor prognosis remains unclear. We investigated miRNA expression in eight open biopsy samples to identify miRNAs predictive of response to induction chemotherapy and thus maybe used for risk stratification therapy. The samples were obtained from four patients with inferior necrosis (Huvos I/II) and four patients with superior necrosis (Huvos III/IV) following induction chemotherapy. We found six miRNAs, including miR-125b and miR-100, that were differentially expressed > 2-fold (p < 0.05) in patients who respond poorly to treatment. The association between poor prognosis and the abundance of miR-125b and miR-100 was confirmed by quantitative reverse transcriptase-polymerase chain reaction in 20 additional osteosarcoma patients. Accordingly, overexpression of miR-125b and miR-100 in three osteosarcoma cell lines enhanced cell proliferation, invasiveness, and resistance to chemotherapeutic drugs such as methotrexate, doxorubicin, and cisplatin. In addition, overexpression of miR-125b blocked the ability of these chemotherapy agents to induce apoptosis. As open biopsy is routinely performed to diagnose osteosarcoma, levels of miR-125b and miR-100 in these samples may be used as basis for risk stratification therapy.",
author = "Daisuke Kubota and Nobuyoshi Kosaka and Tomohiro Fujiwara and Akihiko Yoshida and Yasuhito Arai and Zhiwei Qiao and Fumitaka Takeshita and Takahiro Ochiya and Akira Kawai and Tadashi Kondo",
year = "2016",
doi = "10.1155/2016/1390571",
language = "English",
volume = "2016",
journal = "Sarcoma",
issn = "1357-714X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - MiR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma

AU - Kubota, Daisuke

AU - Kosaka, Nobuyoshi

AU - Fujiwara, Tomohiro

AU - Yoshida, Akihiko

AU - Arai, Yasuhito

AU - Qiao, Zhiwei

AU - Takeshita, Fumitaka

AU - Ochiya, Takahiro

AU - Kawai, Akira

AU - Kondo, Tadashi

PY - 2016

Y1 - 2016

N2 - Osteosarcoma is the most common primary malignancy in bone. Patients who respond poorly to induction chemotherapy are at higher risk of adverse prognosis. The molecular basis for such poor prognosis remains unclear. We investigated miRNA expression in eight open biopsy samples to identify miRNAs predictive of response to induction chemotherapy and thus maybe used for risk stratification therapy. The samples were obtained from four patients with inferior necrosis (Huvos I/II) and four patients with superior necrosis (Huvos III/IV) following induction chemotherapy. We found six miRNAs, including miR-125b and miR-100, that were differentially expressed > 2-fold (p < 0.05) in patients who respond poorly to treatment. The association between poor prognosis and the abundance of miR-125b and miR-100 was confirmed by quantitative reverse transcriptase-polymerase chain reaction in 20 additional osteosarcoma patients. Accordingly, overexpression of miR-125b and miR-100 in three osteosarcoma cell lines enhanced cell proliferation, invasiveness, and resistance to chemotherapeutic drugs such as methotrexate, doxorubicin, and cisplatin. In addition, overexpression of miR-125b blocked the ability of these chemotherapy agents to induce apoptosis. As open biopsy is routinely performed to diagnose osteosarcoma, levels of miR-125b and miR-100 in these samples may be used as basis for risk stratification therapy.

AB - Osteosarcoma is the most common primary malignancy in bone. Patients who respond poorly to induction chemotherapy are at higher risk of adverse prognosis. The molecular basis for such poor prognosis remains unclear. We investigated miRNA expression in eight open biopsy samples to identify miRNAs predictive of response to induction chemotherapy and thus maybe used for risk stratification therapy. The samples were obtained from four patients with inferior necrosis (Huvos I/II) and four patients with superior necrosis (Huvos III/IV) following induction chemotherapy. We found six miRNAs, including miR-125b and miR-100, that were differentially expressed > 2-fold (p < 0.05) in patients who respond poorly to treatment. The association between poor prognosis and the abundance of miR-125b and miR-100 was confirmed by quantitative reverse transcriptase-polymerase chain reaction in 20 additional osteosarcoma patients. Accordingly, overexpression of miR-125b and miR-100 in three osteosarcoma cell lines enhanced cell proliferation, invasiveness, and resistance to chemotherapeutic drugs such as methotrexate, doxorubicin, and cisplatin. In addition, overexpression of miR-125b blocked the ability of these chemotherapy agents to induce apoptosis. As open biopsy is routinely performed to diagnose osteosarcoma, levels of miR-125b and miR-100 in these samples may be used as basis for risk stratification therapy.

UR - http://www.scopus.com/inward/record.url?scp=85005949729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005949729&partnerID=8YFLogxK

U2 - 10.1155/2016/1390571

DO - 10.1155/2016/1390571

M3 - Article

AN - SCOPUS:85005949729

VL - 2016

JO - Sarcoma

JF - Sarcoma

SN - 1357-714X

M1 - 1390571

ER -